BillionToOne shares fall 6% premarket after report criticizes company practices
Key Facts
BillionToOne shares fell 6% in premarket trading on Wednesday, November 18, 2026, after a short seller published a report criticizing the company's practices, according to Investing.com. The site attributed the move to a report by Fuzzy Panda Research, which addressed allegations involving billing, regulatory oversight and clinical claims. The report said the research firm held a short position in the stock, meaning it would benefit if the share price fell. BillionToOne had not publicly responded to the allegations at the time of publication. Investing.com noted that the allegations and financial estimates in the report had not been independently verified.
Among the issues raised in the report was Fuzzy Panda's interpretation of Tennessee state records, which it said showed that the Program Integrity Unit opened an investigation in 2024 after receiving 11 complaints. According to this interpretation, the unit later referred the matter to the Medicaid Fraud Control Unit in the state Bureau of Investigation. The referral represents a procedural step as described in the report, but does not establish that a violation occurred or that formal charges were filed. Investing.com explicitly cautioned that referring a matter to a law enforcement agency does not mean a violation has been established. The allegations in the report therefore remained unresolved at the time of publication, and the report did not provide a final outcome of the investigation.
The report comes as the company had announced strong growth in quarterly revenue. On November 4, BillionToOne said third-quarter revenue was $123.0 million, up 47% from $83.5 million in the same period of 2025. Revenue from clinical prenatal tests was $104.3 million, up 41% year over year. Clinical oncology test revenue reached $17.1 million, up 96% compared with $8.7 million in the third quarter of 2025. The reported figures show different growth rates for the two testing segments, with oncology tests recording the higher rate.
The company said it delivered 206,000 tests in the third quarter, compared with 165,000 tests in the corresponding period of 2025, an increase of 25%. It also raised its fiscal 2026 revenue forecast to a range of $460.0 million to $470.0 million, equivalent to expected growth of 51% to 54% from 2025. The previous forecast range was $450.0 million to $465.0 million. In oncology products, BillionToOne said Northstar Clear, designed to detect molecular residual disease in patients with solid tumors, would be commercially available on December 15, 2026. These results, forecasts and launch plans provide publicly announced operating context for the company, while not in themselves resolving the allegations raised in the short-seller report.